

REMARKS

Claims 21-29 are pending. Claims 1-20 have been canceled. Claims 21-29 have been added. No claims have been allowed.

Applicant has amended to Title and Abstract to delete the phrase "galactomannans, glucomannans and the like". Applicant has also made revisions to the specification to conform same to U.S. practice and to add headings. Paragraph [0033] has been amended to incorporate the text of paragraphs [0037] and [0038], which have been canceled.

Responsive to the provisional rejection of Claims 1-20 under nonstatutory obviousness-type double patenting, Applicant hereby submits a Terminal Disclaimer which disclaims the term of any patent granted on the instant application which would extend beyond the maximum possible term of any patent granted on co-pending U.S. Patent Application Serial No. 10/595,684.

Responsive to the rejection of Claims 1-20 under 35 U.S.C. §112, second paragraph, Applicant submits that such rejections are obviated by the submission of new Claims 21-29.

The Examiner rejected Claims 1-20 under 35 U.S.C. §102(b) as being anticipated by GB 2 257 358 A ("GB '358").

GB '358 discloses use of organic raw materials, such as polysaccharides, for embedding vital substances such as vitamins, enzymes, coenzymes, minerals, trace elements and/or microorganisms, wherein the vital substances are embedded within the organic raw materials separately with regard to function.

From the disclosure and Examples of GB '358, it appears that two or more active substances are together embedded within a given polysaccharide, wherein the reference does not teach the claimed process, in which a polysaccharide is provided in the form of a plurality of granular particles in which individual granular particles include only one active substance, *i.e.*, a first active substance is incorporated into a first granular particle and a second active substance is incorporated into a second granular particle, wherein the first and second granular particles are functionally separated from one another and the active substances thereof do not mix or interact with one another prior to being introduced into the metabolism of a human or animal.

Additionally, GB '358 also does not disclose the process of dependent Claim 29, which calls for the providing step of independent Claim 21 to further comprise providing a

Application Serial No. 10/780,152
Amendment dated September 17, 2007
Reply to Office Action dated April 17, 2007

polysaccharide, incorporating a solution containing the first active substance into the polysaccharide until the first active substance has been fully incorporated; and then incorporating a solution containing the second active substance into the polysaccharide.

In the event Applicant has overlooked the need for an extension of time, payment of fee, or additional payment of fee, Applicant hereby petitions therefor and authorizes that any charges be made to Deposit Account No. 02-0385, Baker & Daniels LLP.

Should the Examiner have any questions regarding any of the above, the Examiner is respectfully requested to telephone the undersigned at 260-424-8000.

Respectfully submitted,



Matthew B. Skaggs
Registration No. 55,814

Attorney for Applicants

MBS/nw

BAKER & DANIELS LLP
111 East Wayne Street, Suite 800
Fort Wayne, IN 46802
Telephone: 260-424-8000
Facsimile: 260-460-1700


Enc. Petition for Extension of Time
 Terminal Disclaimer
 Return Postcard

CERTIFICATION OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on: September 17, 2007

MATTHEW B. SKAGGS, REG. NO. 55,814

Name of Registered Representative



Signature

September 17, 2007

Date